Safety, tolerability, and activity of ALV003: results from two phase 1 single, escalating-dose clinical trials.
Siegel M; Garber ME; Spencer AG; Botwick W; Kumar P; Williams RN; Kozuka K; Shreeniwas R; Pratha V; Adelman DC; Digestive Diseases And Sciences, 2012, vol. 57, issue 2, p 440, ISSN 15732568. ISBN 15732568.

Full Text Resources Located for this Citation

View article on EBSCOhost(Login required)
View article via CrossRef